Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) EBITDA Margin (2018 - 2023)

Endonovo Therapeutics has reported EBITDA Margin over the past 9 years, most recently at 31105.07% for Q3 2023.

  • Quarterly results put EBITDA Margin at 31105.07% for Q3 2023, down 2657242.0% from a year ago — trailing twelve months through Sep 2023 was 13157.95% (up 3536433.0% YoY), and the annual figure for FY2022 was 24380.33%, up 2742602.0%.
  • EBITDA Margin for Q3 2023 was 31105.07% at Endonovo Therapeutics, down from 2502.9% in the prior quarter.
  • Over the last five years, EBITDA Margin for ENDV hit a ceiling of 253289.02% in Q4 2020 and a floor of 276730.62% in Q2 2022.
  • Median EBITDA Margin over the past 5 years was 1882.36% (2021), compared with a mean of 10300.5%.
  • Biggest five-year swings in EBITDA Margin: plummeted -37157826bps in 2021 and later surged 27422772bps in 2023.
  • Endonovo Therapeutics' EBITDA Margin stood at 491.77% in 2019, then skyrocketed by 51606bps to 253289.02% in 2020, then tumbled by -147bps to 118289.24% in 2021, then surged by 125bps to 29458.59% in 2022, then plummeted by -206bps to 31105.07% in 2023.
  • The last three reported values for EBITDA Margin were 31105.07% (Q3 2023), 2502.9% (Q2 2023), and 604.63% (Q1 2023) per Business Quant data.